Clinical features and disease course of patients with juvenile dermatomyositis

International Journal of Rheumatic Diseases

Volumn 16, Issue 5, 2013, Pages 561-567

  Gowdie, Peter J ^a   Allen, Roger C ^a   Kornberg, Andrew J ^a   Akikusa, Jonathan D ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Australasia; Juvenile dermatomyositis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; CELL NUCLEUS ANTIGEN; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; RHEUMATOID FACTOR;

ADOLESCENT; AGE DISTRIBUTION; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; AUSTRALIA; CALCINOSIS; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTRACTURE; DIAGNOSTIC TEST; DISEASE COURSE; DRUG MEGADOSE; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GOTTRON PAPULE; GOWER SIGN; HELIOTROPE RASH; HEPATOMEGALY; HUMAN; HUMAN TISSUE; JUVENILE DERMATOMYOSITIS; LETHARGY; LUNG DISEASE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAR RASH; MALE; MOUTH ULCER; MUSCLE BIOPSY; MYALGIA; NAIL; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; POIKILODERMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; SKIN ULCER; STEROID THERAPY; WEAKNESS; WEIGHT REDUCTION;

AUSTRALASIA; JUVENILE DERMATOMYOSITIS;

ADOLESCENT; AGE OF ONSET; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DIFFUSION OF INNOVATION; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RHEUMATOLOGY; TERTIARY CARE CENTERS; TIME FACTORS; VICTORIA;

EID: 84886584625     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12107     Document Type: Article

References (22)

1. Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28 (4), 833-57.
2. McCann LJ, Juggins AD, Maillard SM et al. (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 years. Rheumatology (Oxford) 45 (10), 1255-60.
3. Mendez EP, Lipton R, Ramsey-Goldman R et al. (2003) US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49 (3), 300-5.
4. Symmons DP, Sills JA, Davis SM (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34 (8), 732-6.
5. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (8), 403-7.
6. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (7), 344-7.
7. Brown VE, Pilkington CA, Feldman BM et al. (2006) An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 45 (8), 990-3.
8. Ng YT, Ouvrier RA, Wu T (1998) Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol 13 (3), 109-12.
9. Constantin T, Ponyi A, Orbán I et al. (2006) National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary-clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 39 (3), 223-32.
10. Pachman LM, Hayford JR, Chung A et al. (1998) Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25 (6), 1198-204.
11. Sallum AM, Kiss MH, Sachetti S et al. (2002) Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 60 (4), 889-99.
12. Huber AM, Lang B, LeBlanc CM et al. (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 (3), 541-9.
13. Sato JO, Sallum AM, Ferriani VP et al. (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27 (6), 1031-8.
14. Ravelli A, Trail L, Ferrari C et al. (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62 (1), 63-72.
15. Stringer E, Singh-Grewal D, Feldman BM (2008) Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 58 (11), 3585-92.
16. Kobayashi S, Higuchi K, Tanaki H et al. (1997) Characteristics of juvenile dermatomyositis in Japan. Acta Paediatr Jpn 39 (2), 257-62.
17. Shehata R, al-Mayouf S, al-Dalaan A, al-Mazaid A, al Balaa S, Bahabri S (1999) Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 17 (1), 115-8.
18. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103 (6), 882-8.
19. Callen JP (1994) Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin North Am 20 (4), 943-53.
20. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47 (4), 505-11.
21. Al-Mayouf S, Al-Mazyed A, Bahabri S (2000) Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19 (2), 138-41.
22. Ramanan AV, Campbell-Webster N, Ota S et al. (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. 121Athritis Rheum 52 (11), 3570-8.